Abbott Defeated In HCV Patent Spat

Law360, New York (January 4, 2007, 12:00 AM EST) -- In a blow to Abbott Laboratories, a federal judge has upheld a jury’s decision to award Belgian biotechnology company Innogenetics NV $7 million in damages in the duo’s long-standing battle over a hepatitis C virus genotyping patent.

On Thursday, Innogenetics revealed that a Wisconsin district judge had sustained the jury’s earlier verdict and damages award, hailing the decision as a victory for innovators.

"Today's ruling sends a message to companies large and small that mistakenly believe they can misappropriate others' innovations without regard for the law,"...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.